Shire: Patent trial and appeal board upholds validity of LIALDA patent
Shire announced that the U.S. Patent & Trademark Office's Patent Trial and Appeal Board has issued their decision upholding the validity of U.S. Patent No. 6,773,720, related to Shire's LIALDA product. The petition seeking to institute inter partes review was filed with the U.S. Patent and Trademark Office's Patent Trial and Appeal Board in April of 2015 by the Coalition For Affordable Drugs II L.L.C. Fund. The PTAB found that the patent was valid in light of the challenges put forward by the petitioner. Shire is pleased with the decision and will continue to vigorously defend its patents to protect the innovation and value Shire products bring to patients. LIALDA remains the only once-daily mesalamine product indicated for both the induction of remission of mild to moderate ulcerative colitis and for the maintenance of remission of UC. There have not been any approvals of generic versions of LIALDA.